Original Research
Accepted on 09 Oct 2026
Efficacy and safety of orelabrutinib plus R-CDOP as first-line therapy in diffuse large B-cell lymphoma with high-risk CNS-IPI: A prospective, multicenter, single-arm, phase II study
in Cancer Epidemiology and Prevention